SGLT2 inhibitors have been associated with diabetic ketoacidosis (DKA), and the DAPA-HF trial showed that all cases of DKA occurred in patients with type-2 DM and that the incidence of DKA was 0.1% with dapagliflozin and 0% with placebo [32]. The gene discussed is SLC5A2; the disease is diabetic ketoacidosis.